News
ORXOF
2.900
NaN%
--
Orexo AB Earnings Call: Science Progress, Cash Strain
TipRanks · 3d ago
Orexo publishes transcript of Q2 2026 earnings call
PUBT · 3d ago
Orexo Advances Nasal Rescue Pipeline as Losses Deepen in Q2 2026
TipRanks · 3d ago
Orexo Q2 FY26 net loss widens to SEK 102.5 million; revenue falls to SEK 3.5 million
PUBT · 3d ago
BRIEF-Orexo Q2 EBIT SEK -103.3 Million
Reuters · 3d ago
Orexo to present Q2 interim report in investor webcast and teleconference
PUBT · 07/10 09:03
Orexo strengthens partnership strategy with new business development chief
TipRanks · 06/09 06:43
Orexo names Raheleh Nassaji SVP business development, adds her to management team
PUBT · 06/09 06:00
OREXO AB - SINGLE NASAL DOSE OF OX390 ACHIEVES TARGETED THERAPEUTIC EXPOSURE
Reuters · 05/19 12:58
Orexo posts positive in‑vivo data for nasal overdose reversal candidate OX390
TipRanks · 05/19 06:52
Orexo reports positive in-vivo study data for OX390 nasal atipamezole absorption
PUBT · 05/19 06:07
Orexo AGM Backs Board, Expands Capital Flexibility and Incentive Plans
TipRanks · 05/07 15:36
Orexo AGM re-elects Friedrich von Bohlen und Halbach as board chair
PUBT · 05/07 15:03
Orexo publishes transcript of Q1 2026 earnings call
PUBT · 04/28 12:50
Orexo Deepens R&D Push as Losses Widen and Bond Redeemed Early
TipRanks · 04/28 05:33
Orexo Q1 operating loss narrows to SEK 75 million; net sales fall to SEK 5 million
PUBT · 04/28 05:05
Orexo to host Q1 interim report presentation and Q&A session
PUBT · 04/21 08:01
Orexo says total shares 37.2 million, total voting rights 35.3 million
Reuters · 04/01 02:00
Orexo updates share and voting structure after class C conversion
TipRanks · 03/31 21:48
Orexo Calls 2026 AGM to Decide on Governance, Capital Measures and Incentive Plan
TipRanks · 03/30 10:51
More
Webull provides a variety of real-time ORXOF stock news. You can receive the latest news about Orexo Ab through multiple platforms. This information may help you make smarter investment decisions.
About ORXOF
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.